HC Wainwright Issues Pessimistic Forecast for RLAY Earnings

Relay Therapeutics, Inc. (NASDAQ:RLAY) – Stock analysts at HC Wainwright reduced their Q3 2026 earnings estimates for Relay Therapeutics in a research note issued to investors on Thursday, August 20th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.37) per share for the quarter, down from their prior estimate of ($0.36). HC Wainwright currently has a “Buy” rating and a $29.00 target price on the stock. The consensus estimate for Relay Therapeutics’ current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Relay Therapeutics’ Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.57) EPS, Q1 2027 earnings at ($0.39) EPS, Q2 2027 earnings at ($0.40) EPS, Q3 2027 earnings at ($0.40) EPS and Q4 2027 earnings at ($0.41) EPS.

Several other research analysts have also recently weighed in on the stock. Zacks Research raised shares of Relay Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, August 20th. JPMorgan Chase & Co. lifted their price objective on Relay Therapeutics from $28.00 to $31.00 and gave the company an “overweight” rating in a research note on Friday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Monday, July 6th. Guggenheim restated a “buy” rating on shares of Relay Therapeutics in a research report on Friday, August 7th. Finally, Raymond James Financial restated a “strong-buy” rating on shares of Relay Therapeutics in a research note on Tuesday, May 19th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $25.92.

Relay Therapeutics Price Performance

NASDAQ RLAY opened at $20.57 on Monday. The company’s 50 day simple moving average is $19.07 and its two-hundred day simple moving average is $14.56. Relay Therapeutics has a 1 year low of $3.44 and a 1 year high of $21.27. The stock has a market capitalization of $4.51 billion, a PE ratio of -13.10 and a beta of 1.69.

Relay Therapeutics (NASDAQ:RLAY) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.02). The company had revenue of $0.35 million for the quarter, compared to the consensus estimate of $0.96 million.

Insider Transactions at Relay Therapeutics

In other Relay Therapeutics news, CEO Sanjiv Patel sold 48,199 shares of Relay Therapeutics stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $19.58, for a total transaction of $943,736.42. Following the completion of the sale, the chief executive officer owned 615,898 shares of the company’s stock, valued at $12,059,282.84. The trade was a 7.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Donald A. Bergstrom sold 2,237 shares of the company’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $18.61, for a total value of $41,630.57. Following the completion of the transaction, the insider owned 407,660 shares of the company’s stock, valued at $7,586,552.60. The trade was a 0.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 409,639 shares of company stock worth $7,233,399. Company insiders own 5.04% of the company’s stock.

Institutional Trading of Relay Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of RLAY. AQR Capital Management LLC grew its position in Relay Therapeutics by 11.9% during the first quarter. AQR Capital Management LLC now owns 364,946 shares of the company’s stock valued at $956,000 after acquiring an additional 38,812 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Relay Therapeutics by 6.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 84,069 shares of the company’s stock worth $221,000 after acquiring an additional 5,238 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Relay Therapeutics by 14.6% in the 1st quarter. Millennium Management LLC now owns 2,942,875 shares of the company’s stock worth $7,710,000 after acquiring an additional 374,491 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Relay Therapeutics in the 1st quarter valued at $53,000. Finally, Woodline Partners LP boosted its stake in shares of Relay Therapeutics by 448.4% in the 1st quarter. Woodline Partners LP now owns 1,518,561 shares of the company’s stock valued at $3,979,000 after purchasing an additional 1,241,657 shares in the last quarter. Hedge funds and other institutional investors own 96.98% of the company’s stock.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.